Cargando…

Aripiprazole in the real-world treatment for irritability associated with autism spectrum disorder in children and adolescents in Japan: 52-week post-marketing surveillance

BACKGROUND: The purpose of this study was to evaluate the post-marketing safety and effectiveness of aripiprazole in treating irritability in pediatric patients (6–17 years) with autism spectrum disorder (ASD) in actual clinical sites of Japan. METHODS: In this post-marketing surveillance, patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sugimoto, Yuna, Yamamura, Kayo, Takayama, Tomoyo, Fukuta, Yasuhiko, Aoki, Kazuo, Mikami, Katsunaka, Tomoda, Akemi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061053/ https://www.ncbi.nlm.nih.gov/pubmed/33888067 http://dx.doi.org/10.1186/s12888-021-03201-6

Ejemplares similares

Aripiprazole in the Treatment of Irritability in Children and Adolescents with Autism Spectrum Disorder in Japan: A Randomized, Double-blind, Placebo-controlled Study
por: Ichikawa, Hironobu, et al.
Publicado: (2016)

The effect of switching from oral low-dose aripiprazole to aripiprazole once-monthly 300 mg on the quality of life in three patients with schizophrenia
por: Suzuki, Hidenobu, et al.
Publicado: (2017)

Aripiprazole for treating irritability in children & adolescents with autism: a systematic review
por: Ghanizadeh, Ahmad, et al.
Publicado: (2015)

Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study
por: Calabrese, Joseph R., et al.
Publicado: (2018)

UK clinical experience up to 52 weeks with linaclotide for irritable bowel syndrome with constipation
por: Yiannakou, Yan, et al.
Publicado: (2018)

Effectiveness and Safety of Golimumab in the Treatment of Ulcerative Colitis: 52-Week Results from Post-Marketing Surveillance in Japan
por: Nakamura, Shiro, et al.
Publicado: (2022)

Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study
por: Peters-Strickland, Timothy, et al.
Publicado: (2015)

Emerging role of aripiprazole for treatment of irritability associated with autistic disorder in children and adolescents
por: Stachnik, Joan, et al.
Publicado: (2010)

Duchenne Muscular Dystrophy Successfully Treated with Aripiprazole in a Patient with Autism Spectrum Disorder Symptoms Including Irritability
por: Noda, Seiya, et al.
Publicado: (2021)

Efficacy and Safety of Aripiprazole for Treatment of Irritability in Children with Autistic Disorder: An Open-Label Study
por: Habibi, Nastaran, et al.
Publicado: (2015)

52 Procedures in 52 Weeks: An Innovative Curriculum for Emergency Medicine Residents
por: Walsh, Ryan, et al.
Publicado: (2017)

The 52-week low formula : a contrarian strategy that lowers risk, beats the market, and overcomes human emotion
por: Wiley, Luke L
Publicado: (2014)

Influence of Maternal Bifidobacteria on the Development of Gut Bifidobacteria in Infants
por: Mikami, Katsunaka, et al.
Publicado: (2012)

Real-World Safety and Efficacy of Glycopyrronium Bromide in Japanese Patients with COPD: A 52-Week Post-Marketing Surveillance
por: Kato, Chihiro, et al.
Publicado: (2022)

Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin–norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study
por: Clayton, Anita H, et al.
Publicado: (2014)

Suicide Leap of an 11-Year-Old Girl with Autism Spectrum Disorder
por: Takahashi, Yuki, et al.
Publicado: (2020)

Aripiprazole: A Review of its Use in the Treatment of Irritability Associated with Autistic Disorder Patients Aged 6–17
por: Douglas-Hall, Petrina, et al.
Publicado: (2011)

Efficacy and Tolerability of Aripiprazole: A 26-Week Switching Study from Oral Antipsychotics
por: Lee, Jung-Sun, et al.
Publicado: (2010)

Biological conversion of aripiprazole lauroxil - An N-acyloxymethyl aripiprazole prodrug
por: Rohde, Morten, et al.
Publicado: (2014)

Chlorine Atoms of an Aripiprazole Molecule Control the Geometry and Motion of Aripiprazole and Deschloro-aripiprazole in Subdomain IIIA of Human Serum Albumin
por: Kawai, Akito, et al.
Publicado: (2022)

Creative 52: weekly projects to invigorate your photography portfolio
por: Adler, Lindsay
Publicado: (2014)

DNA methylation changes in infants between 6 and 52 weeks
por: Wikenius, Ellen, et al.
Publicado: (2019)

Aripiprazole cardiosafety: Is it overestimated?
por: Naguy, Ahmed
Publicado: (2016)

Aripiprazole-induced priapism
por: Trivedi, Satya K., et al.
Publicado: (2016)

Safety and efficacy of etelcalcetide, an intravenous calcimimetic, for up to 52 weeks in hemodialysis patients with secondary hyperparathyroidism: results of a post-marketing surveillance in Japan
por: Yokoyama, Keitaro, et al.
Publicado: (2020)

Real-world Safety and Efficacy of Indacaterol/Glycopyrronium in Japanese Patients with Chronic Obstructive Pulmonary Disease: A 52-week Post-marketing Surveillance
por: Kato, Chihiro, et al.
Publicado: (2021)

Safety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitus
por: Onishi, Yukiko, et al.
Publicado: (2012)

Twice-weekly aripiprazole for treating children and adolescents with tic disorder, a randomized controlled clinical trial
por: Ghanizadeh, Ahmad
Publicado: (2016)

TARC: Turkish aripiprazole consensus report- Aripiprazole use and switching from other antipsychotics to aripiprazole- consensus recommendations by a Turkish multidisciplinary panel
por: Veznedaroglu, Baybars, et al.
Publicado: (2018)

One patient with schizophrenia showed reduced drug-induced extrapyramidal symptoms as a result of an alternative regimen of treatment with paliperidone 3 and 6 mg every other day
por: Suzuki, Hidenobu, et al.
Publicado: (2017)

A Year with Peter Drucker - 52 Weeks of Coaching for Leadership Effectiveness
por: Maciariello, Joseph
Publicado: (2014)

Adjunctive Aripiprazole Treatment for Risperidone-Induced Hyperprolactinemia: An 8-Week Randomized, Open-Label, Comparative Clinical Trial
por: Zhao, Jingyuan, et al.
Publicado: (2015)

Effect of aripiprazole as an adjunct to atypical antipsychotics on weight and metabolic profile: a 12-week open-label trial
por: Gupta, Bhanu, et al.
Publicado: (2021)

Aripiprazole for late-life schizophrenia
por: Rado, Jeffrey, et al.
Publicado: (2010)

Tardive Dyskinesia: Treatment with Aripiprazole
por: Kang, Na-Ri, et al.
Publicado: (2011)

Review of depot aripiprazole for schizophrenia
por: Motiwala, Farha Bilal, et al.
Publicado: (2013)

Aripiprazole-induced skin rash
por: Nath, Santanu, et al.
Publicado: (2016)

Tardive Dystonia Related with Aripiprazole
por: Kim, Sunghwan, et al.
Publicado: (2017)

Aripiprazole-induced transient myopia
por: Cumurcu, Tongabay, et al.
Publicado: (2019)

Serum levels of reactive oxygen metabolites at 12 weeks during tocilizumab therapy are predictive of 52 weeks-disease activity score-remission in patients with rheumatoid arthritis
por: Nakajima, Arata, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_0eqdvrt11sfs52u666a7sfjid1